Axsome Third Quarter 2026 Financial Results - AXSOME THERAPEUTICS INC

Explicit Guidance:

• Revenue Outlook: Management expects "Avelity" (referred to as Ovality/Alveolity in transcript) to generate "at least $8 billion in annual revenue at peak." No specific Q4 2026 or FY 2027 revenue guidance is provided; analysts are explicitly told not to rely on consensus estimates for these periods.
• Financial Expectations: Current cash balance of $314 million is deemed sufficient to fund operations until reaching cash flow positivity.
• Gross Margin Trends: Anticipate gross net discounts for Avelity and Sembravo to increase slightly in Q4 2026 due to seasonality; 2027 gross net discount rates for Avelity are expected to mirror 2026 performance (low 50s to mid-high 40s range) with a slight tick-up in Q4 2026.

Business-Segment Outlook:

• Avelity (Major Depressive Disorder & Alzheimer's Disease Agitation):
  • Demand: Expect "continued acceleration of new patient initiations" and sustained momentum driven by strong underlying demand.
  • New-to-Brand (NBRX): Anticipate NBRX momentum to continue, converting to increasing total prescription growth in coming quarters.
  • Prescribing: Primary care adoption expected to grow, remaining a key driver of long-term growth.
  • Long-Term Care (LTC): Viewed as an "important source of business" with growth rates comparable to the 65+ population; sales cycle noted as longer but early progress positive.
• Sembravo (Migraine):
  • Growth: Expected to continue expanding coverage (currently 57% of lives); positioning as a meaningful treatment for patients with inadequate response to prior acute options.
  • Coverage: Payer access expected to "expand and evolve" moving forward.
• Synocy (Narcolepsy/OSA):
  • Growth: Expect "durable growth" in the weight-promoting agent market and related indications.
  • Infrastructure: Commercial infrastructure noted as robust.

Market and Competitive Outlook:

• Alzheimer's Agitation Market: Described as a "new and developing market with little precedent," requiring significant education on symptoms and diagnosis.
• Competition: Management anticipates the need to differentiate from existing products (e.g., Rixalti, generic antipsychotics) through clinical profile education; notes "inconsistent clinical response" in the narcolepsy market as a differentiator for AXS-12.
• Pricing/Access: No specific pricing guidance provided; management expects patient access to "continue to expand and evolve" in both MDD and Alzheimer's markets.
• Placebo Response: Acknowledges rising placebo rates in schizophrenia trials but plans to utilize proprietary trial design "bells and whistles" to mitigate this risk.

Macro / Industry Outlook:

• Seasonality: Anticipates slight increases in gross net discounts in Q4 due to typical seasonality and accruals for Q1 adjudicated scripts.
• Payer Dynamics: No disruption anticipated from Medicare Advantage plan changes; expects "no major bottlenecks" in distribution or EMR updates.
• Regulatory Environment: FDA PDUFA target date for AXS-12 (cataplexy) set for May 1, 2027; FDA not expected to hold an advisory committee meeting.
• Data Reporting: Third-party script capture rates (e.g., IQVIA, Symphony) may fluctuate due to new pharmacy onboarding and reporting changes.

Strategic Initiatives:

• Pipeline Milestones (Dates):
  • AXS-05 (Smoking Cessation): Top-line results expected in H2 2027.
  • Solv-Re-Amphetamine (ADHD): Top-line results for Focus 2 & 3 (pediatric) expected in H2 2027; NDA filing basis if positive.
  • Solv-Re-Amphetamine (Binge Eating Disorder): Top-line results from ENGAGE trial expected in Q1 2027.
  • Solv-Re-Amphetamine (Shift Work Disorder): Top-line results expected in H2 2027.
  • Solv-Re-Amphetamine (MDD with excessive daytime sleepiness): Enrollment completion expected in H1 2026.
  • AXS-20 (Schizophrenia): Pivotal Phase 3 trial initiation expected in H1 2027; positioning as a first-line therapy.
  • AXS-12 (Narcolepsy): NDA review ongoing; pre-launch activities underway for potential May 2027 approval.
  • AXS-14 (Fibromyalgia): Enrollment completion expected in Q3 2027; NDA filing anticipated shortly after top-line results (potentially <6 months post-data).
  • AXS-17 (Epilepsy): Clinical trials expected to initiate in H1 2027.
• Commercial Expansion: Expanded sales team for Avelity driving adoption in primary care (40% of prescribers in Q3); expected to continue driving prescriber growth.
• M&A/BD: Recent transactions for schizophrenia and epilepsy assets (AXS-17, AXS-20) completed; strategy focused on "tucking in" and developing pipeline assets without impacting investment strategy.

Risks and Headwinds to Outlook:

• Market Education: Significant education required for Alzheimer's agitation diagnosis and symptom identification; early adoption barriers relate to clinician comfort rather than formulary issues.
• Clinical Trial Risks: Potential for rising placebo responses in schizophrenia trials; risk of enrollment delays or per-patient attrition in randomized withdrawal studies (AXS-17).
• Data Reporting: Third-party prescription data capture rates (IQVIA, Symphony) may fluctuate, affecting visibility into trends.
• Affordability: While manageable for most, affordability challenges persist for some patients regarding co-pays, particularly in Medicare.
• Regulatory Uncertainty: Final FDA approval for AXS-12 is contingent on ongoing review progress.

Management Tone on the Future:

• Confidence Level: High confidence in commercial momentum ("robust growth," "well-positioned," "very pleased").
• Stance on Guidance: Firmly declining to provide specific quarterly or annual guidance due to "current expectations and assumptions" subject to risks; explicitly states "we don't give specific guidance."
• Sentiment: Optimistic regarding the transition from new patient initiations to total prescription growth ("NBRX turning into TRX"); emphasizes "operating leverage" and "continued operating leverage."
• Strategic Focus: Belief that the pipeline is "well-positioned to potentially deliver multiple ways of innovation" and that the business is "executing against strategic priorities."

Miscellaneous:

• Product Naming: Transcript contains inconsistent naming for Avelity (Avelity, Ovality, Alveolity, Alvelety) and Synocy (Synosy, Synocy, Cynosi); these refer to the same products.
• Financials: Net loss narrowed to $12.9M ($0.25/share) in Q3 2026; stock-based compensation included $26.4M.
• Stock Performance: Management acknowledged stock down 40-45% since Avelity launch but attributed this to investor expectations rather than internal commercial performance, which is "in line" with internal expectations.